Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “schizophrenia” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 97
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 97 pipeline programs matching "schizophrenia" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

97 results for “schizophrenia” Back to intelligence hub

Search results

Page 3 of 5
  1. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 small molecule active

    1 trial
  2. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    2 trials
  3. NMDAE plus AIFA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial
  4. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  5. OXY-APS

    The George Institute

    schizophrenia or other primary psychotic disorders (SSD)

    phase 2 small molecule active

    1 trial
  6. Pimavanserin 34 milligrams (MG) [Nuplazid]

    Acadia Pharmaceuticals B.V.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial
  7. Placebo

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  8. Placebo

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial
  9. RP5063

    REVIVA PHARMACEUTICALS HOLDINGS, INC.

    Acute Schizophrenia

    phase 2 small molecule completed

    1 trial
  10. Rimonabant

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial
  11. Risperidone

    Indivior Pty Ltd

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  12. S1RA plus NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial
  13. SPD489 (lisdexamfetamine dimesylate)

    Takeda

    Schizophrenia and Predominant Negative Symptoms

    phase 2 small molecule completed

    1 trial
  14. Sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenias

    phase 2 small molecule completed

    1 trial
  15. Sarcosine and D-serine

    Hospital Authority, Hong Kong

    Schizophrenias

    phase 2 small molecule completed

    1 trial
  16. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  17. TAK-041

    NEUROCRINE BIOSCIENCES INC

    Stable Schizophrenia

    phase 2 small molecule completed

    1 trial
  18. TAK-063 20 mg

    Takeda

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  19. armodafinil

    Teva Pharma GmbH

    Schizophrenia

    phase 2 small molecule completed

    2 trials
  20. mutual support group

    Hong Kong Baptist University

    Schizophrenia

    phase 2 other completed

    1 trial
  21. sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial
  22. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial
  23. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 1 small molecule completed

    1 trial
  24. ITI-214 Dose A

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.